Association Between the Dihydrotestosterone Level in the Prostate and Prostate Cancer Aggressiveness Using the Gleason Score

Journal of Urology

Volumn 176, Issue 4, 2006, Pages 1387-1391

  Nishiyama, Tsutomu ^a   Ikarashi, Toshihiko ^b   Hashimoto, Yutaka ^c   Suzuki, Kazuya ^a   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Department of Pathology   (Japan)

^c NIPPON KAYAKU CO LTD   (Japan)

Author keywords

androgens; dihydrotestosterone; prostate; prostatic neoplasms

Indexed keywords

ANDROGEN; ANDROSTANOLONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DERIVATIZATION; DISEASE ASSOCIATION; DISEASE COURSE; ELECTROSPRAY MASS SPECTROMETRY; GLEASON SCORE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SEX HORMONE DETERMINATION; TESTOSTERONE BLOOD LEVEL; TISSUE DISTRIBUTION; TUMOR BIOPSY;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DIHYDROTESTOSTERONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE CONGENERS;

EID: 33748120911     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.06.066     Document Type: Article

References (20)

1. Albertsen P.C., Hanley J.A., and Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293 (2005) 2095
2. Morgentaler A., Bruning III C.O., and DeWolf W.C. Occult prostate cancer in men with low serum testosterone levels. JAMA 276 (1996) 1904
3. Hoffman M.A., DeWolf W.C., and Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer?. J Urol 163 (2000) 824
4. Zhang P.L., Rosen S., Veeramachaneni R., Kao J., DeWolf W.C., and Bubley G. Association between prostate cancer and serum testosterone levels. Prostate 53 (2002) 179
5. Massengill J.C., Sun L., Moul J.W., Wu H., McLeod D.G., Amling C., et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 169 (2003) 1670
6. Isom-Batz G., Bianco Jr. F.J., Kattan M.W., Mulhall J.P., Lilja H., and Eastham J.A. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 173 (2005) 1935
7. Teloken C., Da Ros C.T., Caraver F., Weber F.A., Cavalheiro A.P., and Graziottin T.M. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy. hypogonadism represents bad prognosis in prostate cancer. J Urol 174 (2005) 2178
8. Zagars G.K., Pollack A., and von Eschenbach A.C. Serum testosterone-a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49 (1997) 327
9. Fodstad P., Bjoro T., Torlakovic G., and Fossa S.D. No association of serum gonadal or pituitary hormones with prognostic parameters in stages T1 to T3 PN0M0 prostate cancer. J Urol 168 (2002) 1188
10. Nishiyama T., Hashimoto Y., and Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10 (2004) 7121
11. Iversen P., Rasmussen F., and Christensen I.J. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl 157 (1994) 41
12. Miller L.R., Partin A.W., Chan D.W., Bruzek D.J., Dobs A.S., Epstein J.I., et al. Influence of radical prostatectomy on serum hormone levels. J Urol 160 (1998) 449
13. Prehn R.T. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 59 (1999) 4161
14. Freedland S.J., Isaacs W.B., Platz E.A., Terris M.K., Aronson W.J., Amling C.L., et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy. a search database study. J Clin Oncol 23 (2005) 7546
15. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
16. Andriole G., Bostwick D., Civantos F., Epstein J., Lucia M.S., McConnell J., et al. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer. current state of knowledge. J Urol 174 (2005) 2098
17. Carver B.S., Kattan M.W., Scardino P.T., and Eastham J.A. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 95 (2005) 509
18. Rubin M.A., Allory Y., Molinie V., Leroy X., Faucon H., Vacherot F., et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 66 (2005) 930
19. Li R., Wheeler T., Dai H., Frolov A., Thompson T., and Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate. cancer patients treated with radical prostatectomy. Am J Surg Pathol 28 (2004) 928
20. Ricciardelli C., Choong C.S., Buchanan G., Vivekanandan S., Neufing P., Stahl J., et al. Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. Prostate 63 (2005) 19